Search

Your search keyword '"Kahraman, Seda"' showing total 130 results
Start Over Author "Kahraman, Seda"
130 results on '"Kahraman, Seda"'

1. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Author

Kahraman, Seda, Karakaya, Serdar, Kaplan, Muhammed Ali, Goksu, Sema Sezgin, Ozturk, Akin, Isleyen, Zehra Sucuoglu, Hamdard, Jamshid, Yildirim, Sedat, Dogan, Tolga, Isik, Selver, Celebi, Abdussamet, Gulbagci, Burcu Belen, Paksoy, Nail, Dogan, Mutlu, Turk, Haci Mehmet, Bilici, Ahmet, Tatli, Ali Murat, Akbas, Sinem, Turan, Nedim, Hacibekiroglu, Ilhan, Dogu, Gamze Gokoz, Aydiner, Adnan, Sumbul, Ahmet Taner, Akyurek, Serap, Yalciner, Merih, Demirkazik, Ahmet, Gursoy, Pinar, Aykan, Musa Baris, Sahin, Elif, Karadag, İbrahim, Kostek, Osman, Er, Muhammed Muhiddin, Artaç, Mehmet, Duzkopru, Yakup, Aydin, Dincer, Isik, Deniz, Karakas, Yusuf, Kilickap, Saadettin, Erol, Cihan, Demir, Bilgin, Civelek, Burak, Ergun, Yakup, Akinci, Muhammed Bulent, Dogan, Izzet, Karadurmus, Nuri, Yumuk, Perran Fulden, and Sendur, Mehmet Ali Nahit

Published
2024
Full Text
View/download PDF

3. Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Author

Karacin, Cengiz, Oksuzoglu, Berna, Demirci, Ayşe, Keskinkılıç, Merve, Baytemür, Naziyet Köse, Yılmaz, Funda, Selvi, Oğuzhan, Erdem, Dilek, Avşar, Esin, Paksoy, Nail, Demir, Necla, Göksu, Sema Sezgin, Türker, Sema, Bayram, Ertuğrul, Çelebi, Abdüssamet, Yılmaz, Hatice, Kuzu, Ömer Faruk, Kahraman, Seda, Gökmen, İvo, Sakin, Abdullah, Alkan, Ali, Nayır, Erdinç, Uğraklı, Muzafer, Acar, Ömer, Ertürk, İsmail, Demir, Hacer, Aslan, Ferit, Sönmez, Özlem, Korkmaz, Taner, Celayir, Özde Melisa, Karadağ, İbrahim, Kayıkçıoğlu, Erkan, Şakalar, Teoman, Öktem, İlker Nihat, Eren, Tülay, Erul, Enes, Mocan, Eda Eylemer, Kalkan, Ziya, Yıldırım, Nilgün, Ergün, Yakup, Akagündüz, Baran, Karakaya, Serdar, Kut, Engin, Teker, Fatih, Demirel, Burçin Çakan, Karaboyun, Kubilay, Almuradova, Elvina, Ünal, Olçun Ümit, Oyman, Abdilkerim, Işık, Deniz, Okutur, Kerem, Öztosun, Buğra, Gülbağcı, Burcu Belen, Kalender, Mehmet Emin, Şahin, Elif, Seyyar, Mustafa, Özdemir, Özlem, Selçukbiricik, Fatih, Kanıtez, Metin, Dede, İsa, Gümüş, Mahmut, Gökmen, Erhan, Yaren, Arzu, Menekşe, Serkan, Ebinç, Senar, Aksoy, Sercan, İmamoğlu, Gökşen İnanç, Altınbaş, Mustafa, Çetin, Bülent, Uluç, Başak Oyan, Er, Özlem, Karadurmuş, Nuri, Erdoğan, Atike Pınar, Artaç, Mehmet, Tanrıverdi, Özgür, Çiçin, İrfan, Şendur, Mehmet Ali Nahit, Oktay, Esin, Bayoğlu, İbrahim Vedat, Paydaş, Semra, Aydıner, Adnan, Salim, Derya Kıvrak, Geredeli, Çağlayan, Yavuzşen, Tuğba, Doğan, Mutlu, and Hacıbekiroğlu, İlhan

Published
2023
Full Text
View/download PDF

4. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Author

Karacin, Cengiz, Oksuzoglu, Berna, Demirci, Ayşe, Keskinkılıç, Merve, Baytemür, Naziyet Köse, Yılmaz, Funda, Selvi, Oğuzhan, Erdem, Dilek, Avşar, Esin, Paksoy, Nail, Demir, Necla, Göksu, Sema Sezgin, Türker, Sema, Bayram, Ertuğrul, Çelebi, Abdüssamet, Yılmaz, Hatice, Kuzu, Ömer Faruk, Kahraman, Seda, Gökmen, İvo, Sakin, Abdullah, Alkan, Ali, Nayır, Erdinç, Uğraklı, Muzaffer, Acar, Ömer, Ertürk, İsmail, Demir, Hacer, Aslan, Ferit, Sönmez, Özlem, Korkmaz, Taner, Celayir, Özde Melisa, Karadağ, İbrahim, Kayıkçıoğlu, Erkan, Şakalar, Teoman, Öktem, İlker Nihat, Eren, Tülay, Urul, Enes, Mocan, Eda Eylemer, Kalkan, Ziya, Yıldırım, Nilgün, Ergün, Yakup, Akagündüz, Baran, Karakaya, Serdar, Kut, Engin, Teker, Fatih, Demirel, Burçin Çakan, Karaboyun, Kubilay, Almuradova, Elvina, Ünal, Olçun Ümit, Oyman, Abdilkerim, Işık, Deniz, Okutur, Kerem, Öztosun, Buğra, Gülbağcı, Burcu Belen, Kalender, Mehmet Emin, Şahin, Elif, Seyyar, Mustafa, Özdemir, Özlem, Selçukbiricik, Fatih, Kanıtez, Metin, Dede, İsa, Gümüş, Mahmut, Gökmen, Erhan, Yaren, Arzu, Menekşe, Serkan, Ebinç, Senar, Aksoy, Sercan, İmamoğlu, Gökşen İnanç, Altınbaş, Mustafa, Çetin, Bülent, Uluç, Başak Oyan, Er, Özlem, Karadurmuş, Nuri, Erdoğan, Atike Pınar, Artaç, Mehmet, Tanrıverdi, Özgür, Çiçin, İrfan, Şendur, Mehmet Ali Nahit, Oktay, Esin, Bayoğlu, İbrahim Vedat, Paydaş, Semra, Aydıner, Adnan, Salim, Derya Kıvrak, Geredeli, Çağlayan, Yavuzşen, Tuğba, Doğan, Mutlu, and Hacıbekiroğlu, İlhan

Published
2023
Full Text
View/download PDF

5. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Author

Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Atcı, Muhammed Mustafa, Kahraman, Seda, Kılıçkap, Saadettin, Güven, Deniz Can, Keskinkılıç, Merve, Ayhan, Murat, Eren, Önder, Mustafayev, Fatma Nihan Akkoç, Yaman, Şebnem, Bayram, Ertuğrul, Ertürk, İsmail, Özcan, Erkan, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, Baytemür, Naziyet Köse, Gülmez, Ahmet, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Tatlı, Ali Murat, Ergün, Yakup, Ak, Naziye, Ünal, Çağlar, Özgün, Mehmet Alpaslan, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, and Şendur, Mehmet Ali Nahit

Published
2023
Full Text
View/download PDF

10. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

Author

Akyildiz, Arif, primary, Guven, Deniz Can, additional, Ozluk, Ahmet Anil, additional, Ismayilov, Rashad, additional, Mutlu, Emel, additional, Unal, Olcun Umit, additional, Yildiz, Ibrahim, additional, Iriagac, Yakup, additional, Turhal, Serdar, additional, Akbas, Sinem, additional, Bayram, Ertugrul, additional, Telli, Tugba Akin, additional, Turkoz, Fatma Paksoy, additional, Ozcelik, Melike, additional, Erciyestepe, Mert, additional, Selvi, Oguzhan, additional, Gulbagci, Burcu, additional, Erturk, Ismail, additional, Isleyen, Zehra Sucuoglu, additional, Kahraman, Seda, additional, Akdag, Mutianur Ozkorkmaz, additional, Hamitoglu, Buket, additional, Unek, Ilkay Tugba, additional, Unal, Caglar, additional, Hacibekiroglu, İlhan, additional, Arslan, Cagatay, additional, Azizy, Abdulmunir, additional, Helvaci, Kaan, additional, Demirci, Umut, additional, Dizdar, Omer, additional, Basaran, Mert, additional, Goker, Erdem, additional, Sendur, Mehmet Ali, additional, and Yalcin, Suayib, additional

Published
2023
Full Text
View/download PDF

12. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Author

Erol, Cihan, Sendur, Mehmet Nahit, Bilgetekin, Irem, Garbioglu, Duygu, Hamdard, Jamshid, Akbas, Sinem, Hizal, Mutlu, Arslan, Cagatay, Sevinc, Alper, Kucukarda, Ahmet, Erdem, Dilek, Kahraman, Seda, Cakir, Emre, Demirkiran, Aykut, On, Sercan, Dogan, Izzet, Erdogan, Atike, Koca, Sinan, Kubilay, Pinar, Eren, Orhan, Cilbir, Ebru, Celik, Emir, Araz, Murat, Ozyukseler, Deniz, Yildirim, Mahmut, Bahceci, Aykut, Taskaynatan, Halil, Oyman, Abdilkerim, Deniz, Gulhan, Menekse, Serkan, Kut, Engin, Gulmez, Ahmet, Sakin, Abdullah, Nayir, Erdinc, Acar, Ramazan, Sen, Erdem, Inal, Ali, Turhal, Serdar, Kaya, Ali, Paydas, Semra, Tastekin, Didem, Hacibekiroglu, Ilhan, Cincin, Irfan, Bilici, Ahmet, Mandel, Nil, Dede, Didem, Akinci, Muhammed, Oksuzoglu, Berna, Uncu, Dogan, Yalcin, Bulent, and Artac, Mehmet

Subjects
Metastasis -- Drug therapy -- Patient outcomes, Fluorouracil -- Dosage and administration -- Patient outcomes, Colorectal cancer -- Drug therapy -- Patient outcomes, Drug therapy, Combination -- Patient outcomes, Health
Abstract

Byline: Cihan. Erol, Mehmet. Nahit Sendur, Irem. Bilgetekin, Duygu. Garbioglu, Jamshid. Hamdard, Sinem. Akbas, Mutlu. Hizal, Cagatay. Arslan, Alper. Sevinc, Ahmet. Kucukarda, Dilek. Erdem, Seda. Kahraman, Emre. Cakir, Aykut. Demirkiran, [...]

Published
2022

13. The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study.

Author

Almuradova, Elvina, Seyyar, Mustafa, Arak, Hacı, Tamer, Fatih, Kefeli, Umut, Koca, Sinan, Sen, Erdem, Telli, Tugba Akin, Karatas, Fatih, Gokmen, Ivo, Turhal, Nazım Serdar, Sakalar, Teoman, Ayhan, Murat, Ekinci, Ferhat, Hafizoglu, Emre, Kahraman, Seda, Kesen, Oguzhan, Unal, Caglar, Alan, Ozkan, and Celik, Serdar

Subjects
CASTRATION-resistant prostate cancer, ANDROGEN receptors, PROSTATE-specific antigen
Abstract

Metastatic castration‐resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed to assess the activity and tolerability of Lutetium‐177 (Lu‐177) PSMA‐617 radioligand therapy (RLT) in mCRPC patients across multiple cancer centers in Turkey. The study included 165 patients who received at least one cycle of Lu‐177 PSMA‐617 RLT, with the majority having bone metastases and undergone prior treatments. Prostate‐specific antigen (PSA) levels were assessed before each treatment cycle, and the biochemical response was evaluated in accordance with the Prostate Cancer Work Group 3 Criteria. The PSA decline of ≥50% was classified as a response, while an increase of ≥25% in PSA levels was indicative of progressive disease. Neither response nor progression was considered as stable disease. The Lu‐177 PSMA‐617 RLT led to a significant PSA response, with 50.6% of patients achieving a >50% decrease in PSA levels. Median overall survival (OS) and progression‐free survival were 13.5 and 8.2 months, respectively. Patients receiving Lu‐177 PSMA‐617 RLT in combination with androgen receptor pathway inhibitors (ARPIs) had a higher OS compared to those receiving Lu‐177 PSMA‐617 RLT alone (18.2 vs 12.3 months, P =.265). The treatment was generally well‐tolerated, with manageable side effects such as anemia and thrombocytopenia. This study provides real‐world evidence supporting the effectiveness and safety of Lu‐177 PSMA‐617 RLT in mCRPC patients, particularly when used in combination with ARPIs. These findings contribute to the growing body of evidence on the potential benefits of PSMA‐targeted therapies in advanced prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study

Author

Almuradova, Elvina, primary, Seyyar, Mustafa, additional, Arak, Hacı, additional, Tamer, Fatih, additional, Kefeli, Umut, additional, Koca, Sinan, additional, Sen, Erdem, additional, Telli, Tugba Akin, additional, Karatas, Fatih, additional, Gokmen, Ivo, additional, Turhal, Nazım Serdar, additional, Sakalar, Teoman, additional, Ayhan, Murat, additional, Ekinci, Ferhat, additional, Hafizoglu, Emre, additional, Kahraman, Seda, additional, Kesen, Oguzhan, additional, Unal, Caglar, additional, Alan, Ozkan, additional, Celik, Serdar, additional, Yekeduz, Emre, additional, Omur, Ozgür, additional, and Gokmen, Erhan, additional

Published
2023
Full Text
View/download PDF

15. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Author

Goktas Aydin, Sabin, primary, Kavak, Engin Eren, additional, Topcu, Atakan, additional, Bayramgil, Ayberk, additional, Akgul, Fahri, additional, Kahraman, Seda, additional, Aykan, Musa Baris, additional, Altıntas, Yunus Emre, additional, Helvaci, Kaan, additional, Urun, Yuksel, additional, Bilici, Ahmet, additional, Seker, Mesut, additional, Sendur, Mehmet Ali Nahit, additional, Olmez, Omer Fatih, additional, Acikgoz, Ozgur, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

16. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Author

Kahraman, Seda, primary, Erul, Enes, additional, Seyyar, Mustafa, additional, Gumusay, Ozge, additional, Bayram, Ertugrul, additional, Demirel, Burcin Cakan, additional, Acar, Omer, additional, Aksoy, Sercan, additional, Baytemur, Naziyet Kose, additional, Sahin, Elif, additional, Cabuk, Devrim, additional, Basaran, Gul, additional, Paydas, Semra, additional, Yaren, Arzu, additional, Guven, Deniz Can, additional, Erdogan, Atike Pinar, additional, Demirci, Umut, additional, Yasar, Alper, additional, Bayoglu, İbrahim Vedat, additional, Hizal, Mutlu, additional, Gulbagci, Burcu, additional, Paksoy, Nail, additional, Davarci, Sena Ece, additional, Yilmaz, Funda, additional, Dogan, Ozlem, additional, Orhan, Sibel Oyucu, additional, Kayikcioglu, Erkan, additional, Aytac, Ali, additional, Keskinkilic, Merve, additional, Mocan, Eda Eylemer, additional, Unal, Olcun Umit, additional, Aydin, Esra, additional, Yucel, Hakan, additional, Isik, Deniz, additional, Eren, Onder, additional, Uluc, Basak Oyan, additional, Ozcelik, Melike, additional, Hacibekiroglu, Ilhan, additional, Aydiner, Adnan, additional, Demir, Hacer, additional, Oksuzoglu, Berna, additional, Cilbir, Ebru, additional, Cubukcu, Erdem, additional, Cetin, Bulent, additional, Oktay, Esin, additional, Erol, Cihan, additional, Okutur, Sadi Kerem, additional, Yildirim, Nilgun, additional, Alkan, Ali, additional, Selcukbiricik, Fatih, additional, Aksoy, Asude, additional, Karakas, Yusuf, additional, Ozkanli, Gulhan, additional, Duman, Berna Bozkurt, additional, Aydin, Dincer, additional, Dulgar, Ozgecan, additional, Er, Muhammed Muhiddin, additional, Teker, Fatih, additional, Yavuzsen, Tugba, additional, Aykan, Musa Baris, additional, Inal, Ali, additional, Iriagac, Yakup, additional, Kalkan, Nurhan Onal, additional, Keser, Murat, additional, Sakalar, Teoman, additional, Menekse, Serkan, additional, Kut, Engin, additional, Bilgin, Burak, additional, Karaoglanoglu, Muge, additional, Sunar, Veli, additional, Ozdemir, Ozlem, additional, Turhal, Nazim Serdar, additional, Karadurmus, Nuri, additional, Yalcin, Bulent, additional, and Nahit Sendur, Mehmet Ali, additional

Published
2023
Full Text
View/download PDF

18. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Author

Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Karacin, Cengiz; Oksuzoglu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzaffer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Urul, Enes; Mocan, Eda Eylemer; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Demirel, Burçin Çakan; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdilkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Gülbağcı, Burcu Belen; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İmamoğlu, Gökşen İnanç; Altınbaş, Mustafa; Çetin, Bülent; Uluç, Başak Oyan; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Salim, Derya Kıvrak; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan, School of Medicine, Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Karacin, Cengiz; Oksuzoglu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzaffer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Urul, Enes; Mocan, Eda Eylemer; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Demirel, Burçin Çakan; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdilkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Gülbağcı, Burcu Belen; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İmamoğlu, Gökşen İnanç; Altınbaş, Mustafa; Çetin, Bülent; Uluç, Başak Oyan; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Salim, Derya Kıvrak; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan, and School of Medicine

Abstract

Background: there is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: a total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ? 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: the median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that be, NA

Published
2023

19. Geriatrik hastada dental uygulama esnasında implant anahtarının aspirasyonu: vaka raporu

Author

Günbay, Tayfun, Kenç, Selin, Işık, Gözde, Kahraman, Seda, and Çelik, Ferit

Subjects
Health Care Sciences and Services, Geriatric dentistry,implant screwdriver,aspiration,fluoroscopy, bronchoscopy, Geriatrik diş hekimliği, implant anahtarı, aspirasyon, floroskopi, bronkoskopi, Sağlık Bilimleri ve Hizmetleri
Abstract

The aim of this case report is to present a geriatric patient who had aspirated an implant screwdriver. An 82-year-old male patient involuntarily closed his mouth during the healing cap placement phase of implant treatment, and the implant screwdriver disappeared through the pharynx. As the patient exhibited no signs of airway obstruction, it was considered that the implant screwdriver might have passed into the gastrointestinal tract. However, no foreign object was detected in the esophageal mucosa. Therefore, the procedure was repeated using C arm fluoroscopy for guidance. The examination revealed the presence of the implant screwdriver in the bifurcation of the left lower lobe bronchus, which was confirmed by posterior-anterior chest radiography. The following day, the patient underwent a flexible bronchoscopy, however the screwdriver could not be retrieved during the procedure. Further treatment was refused by the patient. After one month, the implant screwdriver was expelled through the gastrointestinal tract. At the three-year follow-up, there was no evidence of a late complication. Aspiration of screwdrivers and treatment failures of these complications are reported a small number of cases in the geriatric patients. Therefore, documentation of the rare cases is necessary to provide valuable information., Bu vaka raporunun amacı, implant anahtarını aspire etmiş geriatrik bir hastayı sunmaktır. Seksen iki yaşında erkek hasta, implant tedavisinin bir aşaması olan iyileşme başlığının takılması esnasında istemsizce ağzını kapatmış ve implant anahtarı farinkse doğru yer değiştirmiştir. Hastada hava yolu tıkanıklığı bulguları olmadığı için, implant anahtarının gastrointestinal yolağa doğru hareket ettiği düşünülmüştür; ancak özefageal mukozada yabancı cisim saptanmamıştır. Bu nedenle, uygulama C arm floroskopi rehberliğinde tekrarlanmıştır. Değerlendirmede implant anahtarının sol alt lob bronş girişinde olduğu düşünülmüştür ve bu bulgu, posteroanteriyor göğüs radyografisi ile doğrulanmıştır. Takip eden günde, hasta fiberoptik fleksibl bronkoskopiye alınmıştır; ancak implant anahtarı çıkartılamamıştır. İmplant anahtarının çıkarılmasında yaşanılan başarısızlıktan dolayı, hasta tarafından ileri tedaviler reddedilmiştir. Bir ay sonra, implant anahtarı gastrointestinal yolaktan atılmıştır. Üç yıllık takipte, geç dönem komplikasyon ile karşılaşılmamıştır. Geriatrik hastalarda, implant anahtarının yutulması ve bu komplikasyonun tedavisindeki başarısızlıklar az sayıda vaka raporunda bildirilmiştir. Bu nedenle, bu nadir vakaların belgelenmesi, faydalı bilgilerin sağlanması açısından gereklidir.

Published
2022

20. The Optimal Treatment Approaches and Prognostic Factors In Elderly Patients with Advanced Stage Biliary Tract Tumors

Author

Göktaş Aydın, Sabin, primary, Çakan Demirel, Burçin, additional, Bilici, Ahmet, additional, Yilmaz, Cansu, additional, Topçu, Atakan, additional, Aykan, Musa Barış, additional, Kahraman, Seda, additional, Atcı, Muhammed Mustafa, additional, Akbıyık, Ilgın, additional, Akgül, Fahri, additional, Ölmez, Ömer Fatih, additional, and Aydın, Ahmet, additional

Published
2023
Full Text
View/download PDF

21. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

Author

Erol, Cihan, primary, Hafızoğlu, Emre, additional, Aykan, Musa Barış, additional, Güven, Deniz Can, additional, Dursun, Bengü, additional, Hızal, Mutlu, additional, Kahraman, Seda, additional, Şener Dede, Didem, additional, Akıncı, Muhammed Bülent, additional, Karadurmuş, Nuri, additional, Ürün, Yüksel, additional, Algın, Efnan, additional, Yalçın, Şuayib, additional, Yalçın, Bülent, additional, and Şendur, Mehmet Ali Nahit, additional

Published
2023
Full Text
View/download PDF

22. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Author

EROL, Cihan, primary, BARDAKÇI, Murat, additional, HIZAL, Mutlu, additional, KAHRAMAN, Seda, additional, YEKEDÜZ, Emre, additional, GÜVEN, Deniz Can, additional, AYKAN, Musa Barış, additional, AK, Recep, additional, ATEŞ, Öztürk, additional, ŞENER DEDE, Didem, additional, AKINCI, Muhammed Bülent, additional, KARADURMUŞ, Nuri, additional, BAL, Öznur, additional, ÜRÜN, Yüksel, additional, YALÇIN, Şuayib, additional, YALÇIN, Bülent, additional, and ŞENDUR, Mehmet Ali Nahit, additional

Published
2023
Full Text
View/download PDF

24. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Author

Yıldırım, Hasan Çağrı, primary, Mutlu, Emel, additional, Chalabiyev, Elvin, additional, Özen, Miraç, additional, Keskinkılıç, Merve, additional, Ön, Sercan, additional, Çelebi, Abdussamet, additional, Dursun, Bengü, additional, Acar, Ömer, additional, Kahraman, Seda, additional, Aykan, Musa Barış, additional, Kaman, Ömür, additional, Doğan, Akif, additional, Erdoğan, Atike Pınar, additional, Melisa Celayir, Özde, additional, Günenç, Damla, additional, Güven, Deniz Can, additional, Vedat Bayoğlu, İbrahim, additional, Yavuzşen, Tuğba, additional, Hacıbekiroğlu, İlhan, additional, İnanç, Mevlüde, additional, Kılıçkap, Saadettin, additional, Yalçın, Şuayib, additional, and Aksoy, Sercan, additional

Published
2022
Full Text
View/download PDF

25. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Author

Hizal, Mutlu, primary, Bilgin, Burak, additional, Paksoy, Nail, additional, Atcı, Muhammed Mustafa, additional, Kahraman, Seda, additional, Kılıçkap, Saadettin, additional, Güven, Deniz Can, additional, Keskinkılıç, Merve, additional, Ayhan, Murat, additional, Eren, Önder, additional, Mustafayev, Fatma Nihan Akkoç, additional, Yaman, Şebnem, additional, Bayram, Ertuğrul, additional, Ertürk, İsmail, additional, Özcan, Erkan, additional, Korkmaz, Mustafa, additional, Akagündüz, Baran, additional, Erdem, Dilek, additional, Telli, Tuğba Akın, additional, Aksoy, Asude, additional, Üskent, Necdet, additional, Baytemür, Naziyet Köse, additional, Gülmez, Ahmet, additional, Aydın, Dinçer, additional, Şakalar, Teoman, additional, Arak, Hacı, additional, Tatlı, Ali Murat, additional, Ergün, Yakup, additional, Ak, Naziye, additional, Ünal, Çağlar, additional, Özgün, Mehmet Alpaslan, additional, Yalçın, Bülent, additional, Öztop, İlhan, additional, Algın, Efnan, additional, Sakin, Abdullah, additional, Aydıner, Adnan, additional, Yumuk, Perran Fulden, additional, and Şendur, Mehmet Ali Nahit, additional

Published
2022
Full Text
View/download PDF

26. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Author

Goktas Aydin, Sabin, primary, Cakan Demirel, Burcin, additional, Bilici, Ahmet, additional, Topcu, Atakan, additional, Aykan, Musa Barış, additional, Kahraman, Seda, additional, Akbıyık, Ilgın, additional, Atci, Muhammed Mustafa, additional, Olmez, Omer Fatih, additional, Yaren, Arzu, additional, Sendur, Mehmet Ali Nahit, additional, Geredeli, Caglayan, additional, Seker, Mesut, additional, Urun, Yuksel, additional, Karadurmus, Nuri, additional, and Aydin, Ahmet, additional

Published
2022
Full Text
View/download PDF

27. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Author

Hizal, Mutlu, primary, Bilgin, Burak, additional, Paksoy, Nail, additional, Kılıçkap, Saadettin, additional, Atcı, Muhammed Mustafa, additional, Kahraman, Seda, additional, Keskinkılıç, Merve, additional, Bilgetekin, İrem, additional, Ayhan, Murat, additional, Tural, Deniz, additional, Eren, Önder, additional, Akkoç Mustafayev, Fatma Nihan, additional, Yaman, Şebnem, additional, Tatlı, Ali Murat, additional, Bayram, Ertuğrul, additional, Kutlu, Yasin, additional, Ertürk, İsmail, additional, Özcan, Erkan, additional, Gülmez, Ahmet, additional, Korkmaz, Mustafa, additional, Akagündüz, Baran, additional, Erdem, Dilek, additional, Telli, Tuğba Akın, additional, Aksoy, Asude, additional, Üskent, Necdet, additional, İriağaç, Yakup, additional, Baytemür, Naziyet Köse, additional, Aydın, Dinçer, additional, Şakalar, Teoman, additional, Arak, Hacı, additional, Selçukbiricik, Fatih, additional, Ergün, Yakup, additional, Korkmaz, Taner, additional, Ak, Naziye, additional, Ünal, Çağlar, additional, Akdeniz, Nadiye, additional, Özgün, Mehmet Alpaslan, additional, Öksüzoğlu, Berna, additional, Yalçın, Bülent, additional, Öztop, İlhan, additional, Algın, Efnan, additional, Sakin, Abdullah, additional, Aydıner, Adnan, additional, Yumuk, Perran Fulden, additional, and Nahit Şendur, Mehmet Ali, additional

Published
2022
Full Text
View/download PDF

28. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Author

Yumuk, Perran Fulden, Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Atçı, Muhammed Mustafa; Kahraman, Seda; Kılıçkap, Saadettin; Güven, Deniz Can; Keskinkılıç, Merve; Ayhan, Murat; Eren, Önder; Mustafayev, Fatma Nihan Akkoç; Yaman, Şebnem; Bayram, Ertuğrul; Ertürk, İsmail; Özcan, Erkan; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Telli, Tugba Akin; Aksoy, Asude; Uskent, Necdet; Baytemur, Naziyet Köse; Gülmez, Ahmet; Aydın, Dinçer; Sakalar, Teoman; Arak, Hacı; Tatlı, Ali Murat; Ergün, Yakup; Ak, Naziye; Ünal, Çağlar; Özgün, Mehmet Alpaslan; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Sendur, Mehmet Ali Nahit, School of Medicine, Yumuk, Perran Fulden, Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Atçı, Muhammed Mustafa; Kahraman, Seda; Kılıçkap, Saadettin; Güven, Deniz Can; Keskinkılıç, Merve; Ayhan, Murat; Eren, Önder; Mustafayev, Fatma Nihan Akkoç; Yaman, Şebnem; Bayram, Ertuğrul; Ertürk, İsmail; Özcan, Erkan; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Telli, Tugba Akin; Aksoy, Asude; Uskent, Necdet; Baytemur, Naziyet Köse; Gülmez, Ahmet; Aydın, Dinçer; Sakalar, Teoman; Arak, Hacı; Tatlı, Ali Murat; Ergün, Yakup; Ak, Naziye; Ünal, Çağlar; Özgün, Mehmet Alpaslan; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Sendur, Mehmet Ali Nahit, and School of Medicine

Abstract

Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells in patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether the percentage of ALK-positive cells had a predictive effect in patients with advanced NSCLC who received first-line Alectinib as ALK-TKI. Materials and methods This retrospective study included patients with advanced-stage NSCLC who received alectinib as a first-line ALK-TKI and whose percentage of ALK-positive cells was determined by FISH at 27 different centers. Patients who received any ALK-TKI before alectinib were not included in the study. Patients were separated into two groups according to the median (40%) value of the percentage of ALK-positive cells (high-positive group >= 40% and low-positive group < 40%). The primary endpoint was PFS, and the secondary endpoints were OS, ORR, and PFS of the subgroups based on different threshold values for the percentage of ALK-positive cells. Results 211 patients were enrolled (48.3% female, 51.7% male) to study. 37% (n = 78) of the patients had received chemotherapy previously. After a median of 19.4 months of follow-up, the median PFS was not reached in the high-positive group (n = 113), but it was 10.8 months in the low-positive group (n = 98) (HR 0.39; 95% CI 0.25-0.60, p < 0.001). The median OS in the high-positive group was not reached, whereas it was 22.8 months in the low-positive group (HR 0.37; 95% CI 0.22-0.63, p < 0.001). ORR was significantly higher in the high-positive group (87.2 vs. 68.5%; p = 0.002). According to the cut-off values of < 20%, 20-39%, 40-59%, and >= 60%, the median PFS was 4.5, 17.1, and 26 months, respectively, and could not be reached in the >= 60% group. Conclusion Our study demonstrated that the efficacy of alectinib varies significantly ac, NA

Published
2022

29. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.

Author

Kahraman, Seda, Bardakci, Murat, Aykan, Musa B., Yasar, Serkan, Erol, Cihan, Hizal, Mutlu, Bulent Akinci, M., Kos, Fahriye Tugba, Dede, Didem S., Karadurmus, Nuri, Yalcin, Suayib, Sendur, Mehmet Ali N., and Yalcin, Bulent

Subjects
*NEUROENDOCRINE tumors, *LOG-rank test, *PANCREATIC tumors, *NEUROENDOCRINE system, *CLINICAL pathology, *RETROSPECTIVE studies
Abstract

Objective: Neuroendocrine neoplasms(NENs) originate from the diffuse neuroendocrine cell system and constitute a heterogeneous group of tumors exhibiting diverse clinical and biological characteristics. NENs include well‑differentiated neuroendocrine tumors(NETs) and poorly differentiated neuroendocrine carcinomas (NECs). In the present study, we performed a retrospective analysis of patients diagnosed with NET to evaluate clinicopathological characteristics, treatment and outcomes. Material and Methods: Data from 153 patients diagnosed with NET who were treated and followed up at three tertiary care centers from November 2002 to June 2021 were retrospectively evaluated. Clinicopathological and prognostic factors, treatment modalities and survival data were analyzed. Kaplan–Meier analysis was used to assess survival data and comparisons were performed using the logrank test. Results: Median age (IQR) was 53 (18–80) years. 85.6% of the patients had gastro‑entero‑pancreatic (GEP)‑NET. The primary tumor was resected in 95 patients (62.1%) and metastasectomy were performed in 22 patients (14.4%). Seventy‑eight patients received systemic therapy for metastatic disease. Patients were followed up for a median of 22 (IQR = 33.8) months. The estimated one‑year and three‑year survival rate was 89.8% and 74.4%, respectively. Median progression‑free survival (PFS) were 10.1, 8.5, and 4.2 months after first‑, second‑ and third‑line therapy, respectively. Conclusion: The number of systemic treatment options and diagnostic tools for NETs has significantly improved in the last few years. NET classification, which treatment will be more appropriate for which group of patients, the molecular basis of this disease and the development of treatment strategies are open‑ended questions that still need to be investigated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

Author

ERGÜN, Yakup, primary, UÇAR, Gökhan, additional, AKTÜRK ESEN, Selin, additional, BARDAKÇI, Murat, additional, KALKAN, Ziya, additional, URAKÇI, Zuhat, additional, ŞEYRAN, Erdoğan, additional, DOĞAN, Mutlu, additional, İMAMOĞLU, Gökşen İnanç, additional, YAZICI, Ozan, additional, KAHRAMAN, Seda, additional, AÇIKGÖZ, Yusuf, additional, and UNCU, Doğan, additional

Published
2022
Full Text
View/download PDF

33. Clinicopathologİcal Features and Survival Outcomes of 70 Tongue Squamous Cell Carcinoma Patients

Author

Aktürk Esen, Selin, primary, Hastürk, Denizcan, additional, Kahraman, Seda, additional, Ergun, Yakup, additional, Uçar, Gökhan, additional, Açıkgöz, Yusuf, additional, Hafızoğlu, Emre, additional, Bal, Öznur, additional, Algın, Efnan, additional, Köş, Fahriye Tugba, additional, Sendur, Mehmet, additional, and Uncu, Doğan, additional

Published
2022
Full Text
View/download PDF

34. We need a common definition and treatment algorithm for displaced rib fracture

Author

Kavurmacı, Önder, primary, Aydın, Sercan, additional, Gülmez, Barış, additional, Kahraman, Seda, additional, Akçam, Tevfik İlker, additional, Özdil, Ali, additional, Ergönül, Ayşe Gül, additional, Akçay, Onur, additional, Yoldaş, Banu, additional, Türker, Asuman Akın, additional, Zorlu, Ekin, additional, and Karakılıç, Ali, additional

Published
2022
Full Text
View/download PDF

35. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

Author

Ergun, Yakup, primary, Esen, Selin Akturk, additional, Bardakci, Murat, additional, Ucar, Gokhan, additional, Kalkan, Ziya, additional, Urakci, Zuhat, additional, Seyran, Erdogan, additional, Dogan, Mutlu, additional, Eren, Tulay, additional, Aslan, Volkan, additional, Kahraman, Seda, additional, Genc, Emine Eylem, additional, Acikgoz, Yusuf, additional, Dirikoc, Merve, additional, Esen, Irfan, additional, and Uncu, Dogan, additional

Published
2021
Full Text
View/download PDF

36. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer

Author

Kahraman,Seda and Yalcin,Suayib

Subjects
OncoTargets and Therapy
Abstract

Seda Kahraman,1 Suayib Yalcin2 1Y&inodot;ld&inodot;r&inodot;m Beyaz&inodot;t University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey; 2Hacettepe University Institute of Cancer, Department of Medical Oncology, Ankara, TurkeyCorrespondence: Suayib YalcinHacettepe University Institute of Cancer, Department of Medical Oncology, S&inodot;hhiye, Ankara, TurkeyTel +90-5053780639Email syalcin@hacettepe.edu.trAbstract: Gastric cancer (GC) is the fifth most common cancer worldwide. Despite recent improvements in treatment quality and options, advanced gastric cancer remains one of the hardest to cure cancers, with a median overall survival (OS) of 10– 12 months and a 5-year OS of approximately 5– 20%. There is an unmet need for further efforts to palliate disease-related symptoms, improve quality of life, increase tumor response rate, and prolong progression free and overall survival while balancing the toxicities of therapy. The most common type of GC is adenocarcinoma, which demonstrates morphological, biological, and clinical heterogeneity. A plethora of genomic alterations and the activation of numerous molecular pathways including human epidermal growth receptor 2 (HER2), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor-2 (FGFR2), mesenchymal epidermal transforming factor receptor (MET), and the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) are responsible for the complex heterogeneity of GC. Efforts to validate the therapeutic effects of inhibiting some of these aberrantly expressed pathways have failed to lead to a clinically meaningful outcome apart from the overexpression/amplification of the HER2 gene, inhibition of which has had a significant impact on clinical practice. The only available biomarkers to guide the effective treatment of patients with advanced GC are HER2 overexpression, MSI/PD-L1 status, and FGFR alterations. Various anti-HER2 agents have been evaluated after the success of the ToGA trial, but none led to a significant enough clinical improvement to be considered a viable alternative for HER2-targeted therapy in advanced GC until the global Keynote-811 trial, which added pembrolizumab to trastuzumab in combination with chemotherapy. This combination demonstrated a survival advantage for the first time in the 11 years since ToGA. Trastuzumab deruxtecan (T-DXd) was also found to be effective in patients who had already received > 2 previous lines of treatment. Despite these promising avenues, the optimal management of HER-2 positive GC still requires further development.Keywords: gastric cancer, HER-2, trastuzumab, targeted therapy

Published
2021

38. A Generalized Construction for Perfect Autocorrelation Sequences

Author

Özbudak, Ferruh, Tekin, Eda, Kahraman, Seda, Bortaş,, Serdar, Özbudak, Ferruh, Tekin, Eda, Kahraman, Seda, and Bortaş,, Serdar

Abstract

In this paper we generalize a previous construction in order to design perfect autocorrelation sequences over the so-called PSK+ constellation defined by Boztas, and Udaya [2]. We give a number theoretic criterion for the existence of the new sequences with perfect autocorrelation, and discuss some preliminary numerical results on their aperiodic correlations and merit factors., IEEE, IEEE Informat Theory Soc, HUAWEI, VTECH, Qualcomm, Google, Croucher Fdn, IBM, BROADCOM, Mediatek, iSN State Key Lab, INC, ITS, SENG, Hong Kong Polytechn Univ, K C Wong Educ Fdn, NSF, Hong Kong Univ Sci ; Technol, Sch Engn

Published
2021

40. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors.

Author

Ergun, Yakup, Esen, Selin Akturk, Bardakci, Murat, Ucar, Gokhan, Kalkan, Ziya, Urakci, Zuhat, Seyran, Erdogan, Dogan, Mutlu, Eren, Tulay, Aslan, Volkan, Kahraman, Seda, Genc, Emine Eylem, Acikgoz, Yusuf, Dirikoc, Merve, Esen, Irfan, and Uncu, Dogan

Subjects
ABO blood group system, IMMUNE checkpoint inhibitors, BLOOD groups, RH factor, BLOOD testing, IMMUNE response
Abstract

BACKGROUND: The relationship of the ABO blood group system with the immune response is known, but its relationship with immune checkpoint inhibitors (ICIs) has not been clearly investigated until now. OBJECTIVE: In this study, the relationship between different blood groups and nivolumab treatment response in patients with advanced malignant melanoma was investigated. METHODS: The data of patients who used nivolumab for advanced malignant melanoma between April 2018 and April 2021 were retrospectively reviewed. RESULTS: A total of 73 patients were included in the study. In the progression-free survival (PFS) analysis according to blood groups, it was 3.9 months, 16.1 months, 20.0 months and 3.0 months for A, B, AB and O, respectively (p = 0.1). Overall survival (OS) analysis according to blood groups was 5.1 months, 25.0 months, 20.0 months and 9.3 months for A, B, AB and O, respectively (p = 0.1). The B antigen group (B or AB) had significantly longer PFS and OS than the non-B antigen group (A or O) (16.1 vs. 3.5 months for PFS, respectively, p = 0.03; 20.0 vs. 7.4 months for OS, respectively, p = 0.02). CONCLUSIONS: The presence of B antigen provides a significant advantage in terms of survival in patients using ICIs for advanced melanoma. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Polikistik over sendromu'nda serum dipeptidil peptidaz-4 (DPP-4), adenozin deaminaz (ADA) aktiviteleri ve oksidatif stres belirteçlerinin değerlendirilmesi

Author

Kahraman, Seda, Eroğlu Altınova, Alev, and İç Hastalıkları Anabilim Dalı

Subjects
Adenosine deaminase, Oxidative stress, Endocrinology and Metabolic Diseases, Endokrinoloji ve Metabolizma Hastalıkları, Dipeptidyl-peptidases and tripeptidyl-peptidases, Polycystic ovary syndrome
Abstract

Polikistik over sendromu (PKOS), yalnızca reprodüktif bir hastalık olmayıp aynı zamanda uzun vadeli sağlık riskleri ile ilişkili görülen heterojen, metabolik bir hastalıktır. İnsülin direncinin ve metabolik bozuklukların yanı sıra, PKOS'lu kadınlarda, kronik düşük dereceli inflamasyon ve artmış oksidatif stres gösterilmiştir. DPP-4 enziminin metabolik ve inflamatuar hastalıkların patofizyolojisinde rol oynayabileceği düşünülmektedir. DPP-4 ayrıca ADA enzimiyle bağlanmaktadır. ADA ile DPP-4'ün etkileşimi, T hücre proliferasyonunda artış ve sitokin sentezi ile sonuçlanmaktadır. ADA aktivitesinin artması halinde, azalan adenozin düzeyleri ile birlikte insülin direnci, hücre proliferasyonu, inflamasyonun indükleneceği öne sürülmektedir. Bu çalışmada, PKOS'lu hastalarda insülin direnci ve inflamasyon ile ilişkili olan DPP-4 ve ADA aktivitelerini, oksidatif stres parametrelerinden serum NO düzeyi ve NOS aktivitesini kontrollerle karşılaştırmalı bir şekilde ölçmeyi, kendi aralarında ve metabolik parametrelerle olası ilişkilerini incelemeyi planladık. Ayrıca obez ve nonobez olarak 2 altgruba ayırdığımız hasta ve kontrol grubunu aynı parametreler açısından araştırdık. Çalışmaya PKOS'lu 52 kadın ve 41 sağlıklı kontrol alındı. PKOS'lu hasta ve kontrol grubunun DPP-4 aktivite düzeyleri benzer tespit edildi (19,54 ± 7,01 ve 18,24 ± 6,73 IU/l; p=0,369). Serum ADA aktivite düzeyleri PKOS grubunda kontrol grubuna göre istatiksel olarak anlamlı şekilde yüksek bulundu (0,33 (0,17-0,67) ve 0,26 (0,12-0,60) IU/l; p=0,006). Serum NO düzeyleri PKOS grubunda kontrol grubuna göre istatiksel olarak anlamlı şekilde yüksek bulundu (24,5 (13,25-58) ve 12,25 (6-24,50) µmol/l; p

Published
2017

47. Siyanobakteriler ve toksinleri

Author

Kahraman, Seda Dicle, Küplülü, Özlem, Meslek Yüksekokulları, Espiye Meslek Yüksekokulu, Gıda İşleme Bölümü, and Kahraman, Seda Dicle

Subjects
Siyanotoksin, Siyanobakter,siyanotoksin,su hijyeni, Su Hijyeni, Siyanobakter, Cyanobacteria,cyanotoxin,water hygiene
Abstract

Tatlı su kaynakları açısından son derece zengin olan ülkemizde su kirliliğinin artışı siyanobakteriyel toksinlerin yaratacağı risklerin önemli bir işareti olmaktadır. Plansız yerleşim ve sanayi atıklarının hemen hemen hiç işlem görmeden iç sulara deşarj edilmesi bu durumun en önemli nedeni olup birçok göl, baraj gölü ve akarsuda su kalitesinin bozulmasına ve siyanobakteriyel kümelerin oluşumuna ortam hazırlamaktadır. Yüzey sularında ötrofi kasyonla birlikte aşırı alg artışı, suların kullanımını sınırlamakta, toksik türlerin bir araya gelmesiyle dünyadaki su kaynakları ve kıyı sularında insan sağlığı için büyük bir tehlike oluşmaktadır.İçerdikleri fotosentetik pigmentler nedeniyle mavi yeşil algler olarak adlandırılan siyanobakterilerin karasal ve kıyı sularında bulunan en az 46 türü omurgalılarda toksik etki oluşturmaktadır. Bu toksinler etkileri açısından; hepatotoksin, nörotoksin ve sitotoksinler olarak sınıfl andırılmakta olup, kimyasal olarak da siklik peptitler (hepatotoksik, mikrosistin ve nodularin), alkaloidler (nörotoksik, anatoksin ve saksitoksin) ve LPS (Lipopolisakarit) endotoksinler olarak üç ayrı grupta incelenmektedirler. Bu derlemede, siyanobakterilerin toksinleri ve yapıları, etki mekanizmaları, sağlık üzerine etkileri, siyanotoksin içeren suların arıtılması ve içme sularında buna ilişkin yapılan düzenlemeler konusunda derlenen bilgiler sunulacaktır, Even though we are rich in fresh water resources, the increase in water pollution is a sign of a signifi cant increase in the risks created by cyanobacterial toxins. Unplanned urban settlements and industrial waste discharge are the most important reasons for this situation and this also prepares the ground for the water quality degradation at many lakes, dam lakes and rivers and the formation of cyanonabacterial clusters. Eutrophication in surface waters with excessive algae growth, restricts the usage of water, and with the combination of toxic species in coastal waters human health is put in great danger.Because of the fact that blue-green algae cyanobactacretrias contain photosynthetic pigments, they have toxic effects on at least 46 types of vertebrates that live in interrestrialand coastal waters. Based on their effects, these toxins are classifi ed as hepatotoxin, neurotoxin and sitotoxins, and chemically they are analyzed in three separate groups: cyclic peptides (hepatotoxic, microcystins and nodular), alkaloids (neurotoxic, anatoxin and saksitoxin) and LPS. In this paper, cyanobacteria toxins and their structures, effect mechanisms, their effects on health, water treatment containing cyanotoxin and arrangements on drinking water will be discussed

Published
2012

48. Optimal frekans atlamalı diziler

Author

Saygı, Zülfikar, Kahraman, Seda, Saygı, Zülfikar, and Kahraman, Seda

Abstract

Bu tezin amacı, Frekans Atlamalı Kod Bölü¸sümlü Çoklu Eri¸sim1 (FH-CDMA), Bluetoothve ultra geni¸s bant gibi popüler sistemlerde kullanılan Optimal Frekans Atlamalı Dizilerin(FHS lerin) olu¸sturulmasıdır. Literatürde optimalli?gi belirleyen sınırlar bulunmaktadır. Buradakioptimallik Lempel-Greenberger ve Peng-Fan anlamındadır. Bu tezde, 1974 den bugüneyayımlanmı¸s optimal FHS üretim metodları incelenmi¸s ve bir tabloda toplanmı¸stır. AyrıcaLempel-Greenberger Sınırı nın keskin bir sınır olup olmadı?gının incelenmesi için 1974 teyayımlamı¸s makalede bulunun optimallik sınırı ve ispatı verilmi¸stir. FHS lerin olu¸sturulmasındakullanılan cebirsel, kombinatorik vs. gibi bir çok metod vardır. Bunların içindencebirsel bir üretim metodu olan ?Iz Fonksiyonu ile üretim yapan 4 makale incelenmi¸s ve bunlarınMAGMA ile gerçekle¸stirimi yapılarak örnekleri incelenmi¸stir. Ayrıca girilen parametreleregöre FHS olu¸sturan yeni bir MAGMA kodu yazılmı¸stır ve yeni optimal dizilerin varlı?gıincelenmi¸stir. Sabit parametreler için optimal FHS ler bulunmu¸stur ancak bunlar henüz birkurala oturtulamamaktadır. Yeni optimal FHS üretim arayı¸sımız devam etmekte olup ilerleyençalı¸smalarımızda, ?Iz Fonksiyonunun yanı sıra di?ger üretim metodları için de benzer bir çalı¸smayürütülebilir.The purpose of this thesis is constructing Optimal Frequency Hopping Sequences (FHSs)which are used in popular systems such as Frequency Hopping-Code Division Multiple Access(FH-CDMA), Bluetooth and Ultra-Wide Band. There are bounds in literature determining optimality.The optimality here is by means of Lempel-Greenberger and Peng-Fan. In this thesis,construction methods of optimal FHSs published since 1974 are analysed and gathered in atable. In addition, so as to examine the sharpness of Lempel-Greenberger Bound, the optimalitybound and its proof given in the paper published in 1974 take place. There are severalmethods for constructing optimal FHSs like algebraic, combinatorial e.t.c.. Four papers givingalgeb

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results